At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BPTH Bio-Path
Post-Market Trading 05-03 19:42:15 EDT
2.61
-0.05
-1.88%
盘后2.61
+0.00+0.07%
19:13 EDT
High2.82
Low2.50
Vol276.54K
Open2.55
D1 Closing2.66
Amplitude12.03%
Mkt Cap4.09M
Tradable Cap1.82M
Total Shares1.57M
T/O738.28K
T/O Rate39.62%
Tradable Shares697.90K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Bio-Path files to sell 484K shares of common stock for holders
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.